Evidence map›Paper›PMID 24504018›Full record

ArticlePloS one2014

Decreased expression of the GATA3 gene is associated with poor prognosis in primary gastric adenocarcinoma.

Rajiv Prasad Keshari, Wei Wang, Yu Zhang, Dan-dan Wang, Yuan-fang Li, Shu-qiang Yuan, Hai-bo Qiu, Chun-yu Huang, Yong-ming Chen, Jian-chuan Xia and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. GATA3 Expression in Human Tumors: A Tissue Microarray Study on 16,557 Tumors.Pathobiology : journal of immunopathology, molecular and cellular biology · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Rajiv Prasad KeshariState Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China ; Department of Gastric and Pancreatic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China ; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Wei WangState Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China ; Department of Gastric and Pancreatic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China ; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Yu ZhangState Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China ; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China ; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Dan-dan WangState Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China ; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Yuan-fang LiState Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China ; Department of Gastric and Pancreatic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China ; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Shu-qiang YuanState Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China ; Department of Gastric and Pancreatic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China ; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Hai-bo QiuState Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China ; Department of Gastric and Pancreatic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China ; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Chun-yu HuangState Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China ; Department of Gastric and Pancreatic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China ; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Yong-ming ChenState Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China ; Department of Gastric and Pancreatic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China ; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Jian-chuan XiaState Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China ; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Zhi-wei ZhouState Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China ; Department of Gastric and Pancreatic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China ; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Sun Yat-sen University Cancer Center · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGATA binding protein 3 (GATA3) was recently proposed to function as a tumor suppressor gene in some types of human cancer. This study aims to investigate GATA3 expression and its prognostic significance in primary gastric adenocarcinoma. METHODOLOGY/PRINCIPAL

findingsUsing real-time quantitative PCR (RT-qPCR) and immunohistochemical staining methods, GATA3 expression was analyzed in tissue samples from a consecutive series of 402 gastric adenocarcinoma patients who underwent resections between 2003 and 2006. The relationship between GATA3 expression, clinicopathological factors, and patient survival was investigated. The expression status of GATA3 was shown to be clearly reduced in the tumor tissue samples compared with that in the matched adjacent non-tumor tissue samples by RT-qPCR (P = 0.0014). Immunohistochemistry analysis indicated that GATA3 expression was significantly decreased in 225 of the 402 (56%) gastric adenocarcinoma cases. Reduced GATA3 expression was also observed in patients with large tumors (P = 0.017), signet ring cell carcinoma or mucinous carcinoma (P = 0.005) and tumors with lymphatic or venous invasion (P = 0.040). Additionally, reduced expression of GATA3 was more commonly observed in tumors that were staged as T4a/b (P<0.001), N3 (P<0.001), or M1 (P<0.001). Kaplan-Meier survival curves revealed that reduced expression of GATA3 was associated with poor prognosis in gastric adenocarcinoma patients (P<0.001). Multivariate Cox analysis identified GATA3 expression as an independent prognostic factor for overall survival (HR = 5.375, 95% CI = 3.647-7.921, P<0.001). To investigate the predictive ability of the models with and without containing GATA3 gene expression, Harrell's c-index was calculated as a measure of predictive accuracy of survival outcome. The c-index values revealed that model containing GATA3 expression (c-index = 0.897) had superior discrimination ability to the model without containg it (c-index = 0.811). CONCLUSIONS/SIGNIFICANCE: Our data suggest that GATA3 plays an important role in tumor progression and that reduced GATA3 expression independently predicts an unfavorable prognosis in primary gastric adenocarcinoma patients.

Indexed as

AdenocarcinomaAgedFemaleGastrectomyGATA3 Transcription FactorGene Expression Regulation, NeoplasticGenes, NeoplasmHumansImmunohistochemistryKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisPrognosisReal-Time Polymerase Chain ReactionRNA, MessengerGATA3 protein, humanGATA3 Transcription FactorRNA, Messenger

Identifiers

PMID24504018
PMCPMC3913598
OpenAlexW2008844717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.